Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy” (Annals of Oncology (2020) 31(S4) (S472–S473), (S0923753420406507), (10.1016/j.annonc.2020.08.654))

S. V. Liu; F. De Braud; A. Drilon; R. C. Doebele; M. R. Patel; B. C. Cho; M. J. Ahn; C. H. Chiu; A. F. Farago; K. Goto; J. Lee; Y. Ohe; S. H.I. Ou; P. Cassier; D. S.W. Tan; G. A. Otterson; L. Veronese; S. Osborne; B. Simmons; S. Siena

doi:10.1016/j.annonc.2021.01.008

Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy” (Annals of Oncology (2020) 31(S4) (S472–S473), (S0923753420406507), (10.1016/j.annonc.2020.08.654))

S. V. Liu, F. De Braud, A. Drilon, R. C. Doebele, M. R. Patel, B. C. Cho, M. J. Ahn, C. H. Chiu, A. F. Farago, K. Goto, J. Lee, Y. Ohe, S. H.I. Ou, P. Cassier, D. S.W. Tan, G. A. Otterson, L. Veronese, S. Osborne, B. Simmons, S. Siena

Department of Internal Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The organisers regret that the table presented in this abstract was incorrect. The correct table is as follows: [Table presented] The organisers would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	577
Number of pages	1
Journal	Annals of Oncology
Volume	32
Issue number	4
DOIs	https://doi.org/10.1016/j.annonc.2021.01.008
Publication status	Published - 2021 Apr

Bibliographical note

Publisher Copyright:
© 2021 European Society for Medical Oncology

All Science Journal Classification (ASJC) codes

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2021.01.008

Fingerprint

Dive into the research topics of 'Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy” (Annals of Oncology (2020) 31(S4) (S472–S473), (S0923753420406507), (10.1016/j.annonc.2020.08.654))'. Together they form a unique fingerprint.

Cite this

Liu, S. V., De Braud, F., Drilon, A., Doebele, R. C., Patel, M. R., Cho, B. C., Ahn, M. J., Chiu, C. H., Farago, A. F., Goto, K., Lee, J., Ohe, Y., Ou, S. H. I., Cassier, P., Tan, D. S. W., Otterson, G. A., Veronese, L., Osborne, S., Simmons, B., & Siena, S. (2021). Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy” (Annals of Oncology (2020) 31(S4) (S472–S473), (S0923753420406507), (10.1016/j.annonc.2020.08.654)). Annals of Oncology, 32(4), 577. https://doi.org/10.1016/j.annonc.2021.01.008

Liu, S. V. ; De Braud, F. ; Drilon, A. et al. / Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours : Analysis of response by line of therapy” (Annals of Oncology (2020) 31(S4) (S472–S473), (S0923753420406507), (10.1016/j.annonc.2020.08.654)). In: Annals of Oncology. 2021 ; Vol. 32, No. 4. pp. 577.

@article{af49e1ad520945aa98be657794c1e0ab,

title = "Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy” (Annals of Oncology (2020) 31(S4) (S472–S473), (S0923753420406507), (10.1016/j.annonc.2020.08.654))",

abstract = "The organisers regret that the table presented in this abstract was incorrect. The correct table is as follows: [Table presented] The organisers would like to apologise for any inconvenience caused.",

author = "Liu, {S. V.} and {De Braud}, F. and A. Drilon and Doebele, {R. C.} and Patel, {M. R.} and Cho, {B. C.} and Ahn, {M. J.} and Chiu, {C. H.} and Farago, {A. F.} and K. Goto and J. Lee and Y. Ohe and Ou, {S. H.I.} and P. Cassier and Tan, {D. S.W.} and Otterson, {G. A.} and L. Veronese and S. Osborne and B. Simmons and S. Siena",

note = "Publisher Copyright: {\textcopyright} 2021 European Society for Medical Oncology",

year = "2021",

month = apr,

doi = "10.1016/j.annonc.2021.01.008",

language = "English",

volume = "32",

pages = "577",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "4",

}

Liu, SV, De Braud, F, Drilon, A, Doebele, RC, Patel, MR, Cho, BC, Ahn, MJ, Chiu, CH, Farago, AF, Goto, K, Lee, J, Ohe, Y, Ou, SHI, Cassier, P, Tan, DSW, Otterson, GA, Veronese, L, Osborne, S, Simmons, B & Siena, S 2021, 'Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy” (Annals of Oncology (2020) 31(S4) (S472–S473), (S0923753420406507), (10.1016/j.annonc.2020.08.654))', Annals of Oncology, vol. 32, no. 4, pp. 577. https://doi.org/10.1016/j.annonc.2021.01.008

Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours : Analysis of response by line of therapy” (Annals of Oncology (2020) 31(S4) (S472–S473), (S0923753420406507), (10.1016/j.annonc.2020.08.654)). / Liu, S. V.; De Braud, F.; Drilon, A. et al.

In: Annals of Oncology, Vol. 32, No. 4, 04.2021, p. 577.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours

T2 - Analysis of response by line of therapy” (Annals of Oncology (2020) 31(S4) (S472–S473), (S0923753420406507), (10.1016/j.annonc.2020.08.654))

AU - Liu, S. V.

AU - De Braud, F.

AU - Drilon, A.

AU - Doebele, R. C.

AU - Patel, M. R.

AU - Cho, B. C.

AU - Ahn, M. J.

AU - Chiu, C. H.

AU - Farago, A. F.

AU - Goto, K.

AU - Lee, J.

AU - Ohe, Y.

AU - Ou, S. H.I.

AU - Cassier, P.

AU - Tan, D. S.W.

AU - Otterson, G. A.

AU - Veronese, L.

AU - Osborne, S.

AU - Simmons, B.

AU - Siena, S.

PY - 2021/4

Y1 - 2021/4

N2 - The organisers regret that the table presented in this abstract was incorrect. The correct table is as follows: [Table presented] The organisers would like to apologise for any inconvenience caused.

AB - The organisers regret that the table presented in this abstract was incorrect. The correct table is as follows: [Table presented] The organisers would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85100201810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100201810&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.01.008

DO - 10.1016/j.annonc.2021.01.008

M3 - Comment/debate

AN - SCOPUS:85100201810

SN - 0923-7534

VL - 32

SP - 577

JO - Annals of Oncology

JF - Annals of Oncology

IS - 4

ER -

Liu SV, De Braud F, Drilon A, Doebele RC, Patel MR, Cho BC et al. Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy” (Annals of Oncology (2020) 31(S4) (S472–S473), (S0923753420406507), (10.1016/j.annonc.2020.08.654)). Annals of Oncology. 2021 Apr;32(4):577. doi: 10.1016/j.annonc.2021.01.008

Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy” (Annals of Oncology (2020) 31(S4) (S472–S473), (S0923753420406507), (10.1016/j.annonc.2020.08.654))

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this